IDO1 and neoplasm: Collectively, our study is the first to delineate how IDO1, when expressed by cancer cells, modulates glycolysis, filling a previously unexplored gap regarding IDO1's distinct impact on glucose metabolism across different cell types and pathological states, especially within the intricate tumor microenvironment.